Xplico

What Xplico does

Xplico ApS is a Danish private limited company founded in 2005 and headquartered in Glostrup, Denmark, providing valuation tools and consulting services exclusively to the life science industry. The company sells two core products built on Microsoft Excel with VBA: Xplico Evaluator, a flexible valuation and risk-assessment tool for projects, portfolios, and companies incorporating risk-adjusted NPV (rNPV), sensitivity analysis and tornado diagrams, and scenario modeling for up to 10 cases; and Xplico CapTable, a standardized capitalization management tool with waterfall analysis and infographic outputs for tracking multi-layered ownership, warrants, and exit scenarios. The third offering is a professional consulting service that delivers 75-100 page PowerPoint valuation reports within roughly one month of engagement.

Xplico's revenue model combines a recurring monthly subscription for the Evaluator Biotech Package (described as a low fixed monthly fee), one-time customized licensing of CapTable, and quote-based multi-year consulting engagements. The company operates with a sales-led, field-driven go-to-market, relying on direct outreach by the CEO (Uffe Boesen) and 6-8 annual international conference appearances (NLS Days, IPLS, LSX World Congress, Bio-Europe) as the dominant customer acquisition channels. It supports more than 100 life science companies across the EU, US, and Asia on a daily basis, with stated end-customers spanning biotech, pharma, and medtech segments. The business is bootstrapped with no external funding rounds, has offices in Denmark, Sweden, and France, and has been recognized as a Børsen Gazelle Company for four consecutive years as of October 2024.

Name

Xplico

Legal name

Xplico ApS

Website

https://xplico.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Xplico ApS is a Denmark-based consultancy and software vendor providing Excel-based valuation tools (Evaluator, CapTable) and consulting services to more than 100 life science companies across the EU, US, and Asia for project, portfolio, and cap table valuation.

Ownership category

akta.pro rank

Product category

Life Science Valuation Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372), Investment Advice (6282)

akta.pro primary industry

Financial Planning & Analysis (FP&A) & BI (HDAEAMAG)

Keywords

• Life science valuation
• Biotech valuation tools
• Risk-adjusted NPV
• Capitalization management
• Valuation consulting

Headquarters

HQ city

Glostrup

HQ country

Denmark

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Xplico Evaluator (Biotech Package): Monthly subscription for valuation tool, training, and valuation support with access to latest market and benchmark data. Fixed monthly fee model providing ongoing product updates and consulting backup.
2. Consulting Services: One-time valuation reports delivered as 75-100 page PowerPoint presentations within one month of contract signing. Includes business case valuation, market research references, deal term analysis, and sensitivity scenarios.
3. Xplico CapTable: Excel-based capitalization tool sold as a customized solution with training and ongoing support. Pricing based on company requirements, shareholder register, and articles of association customization.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Xplico develops and markets two Microsoft Excel/VBA-based software products—Xplico Evaluator (a valuation tool with integrated risk-adjusted NPV and sensitivity analysis) and Xplico CapTable (a capitalization management tool)—alongside professional valuation consulting services. All offerings are tailored specifically for biotech, pharma, and medtech companies to support project valuation, partnering negotiations, portfolio management, funding rounds, and M&A decisions.

Product overview

Xplico offers a portfolio of three interconnected solutions for the life science industry: Xplico Evaluator is the core Excel-based valuation tool for project and company valuation with integrated risk assessment; Xplico CapTable is an Excel-based capitalization management tool for tracking ownership structures and exit scenarios; and Consulting Services provides full-service valuation reports and support. Both Evaluator and CapTable are available as standalone Excel-based tools with training and support, while consulting services offer customized valuation reports for companies needing external validation.

Differentiator

Problem solved

Functional benefit

Brands

• Xplico Evaluator: An easy-to-use, flexible Microsoft Excel-based valuation tool with integrated risk assessment and powerful analysis features for the life science industry. Used for project valuation, partnering, portfolio management, funding, company valuation, and acquisitions.
• Xplico CapTable

Products and services

• Xplico Evaluator

Quantifiable outcome

• Client signed partner agreement with improved deal terms after using Xplico Evaluator to challenge and optimize proposed terms
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• PharmaVentures: PharmaVentures provides transaction advisory, licensing, and valuation services to pharma and biotech companies. Like Xplico, it focuses on supporting deal-making and portfolio decisions across the life sciences value chain.
• Back Bay Life Science Advisors: Back Bay provides strategic advisory and capital markets services to life science companies. Comparable to Xplico in serving biotech/pharma CFOs and BD leaders on valuation, financings, and M&A.
• Locust Walk: Locust Walk is a life science-focused transaction advisory firm supporting biotech partnering, financings, and M&A. Closely comparable to Xplico in vertical specialization and target customer (biotech/pharma senior leadership).
• Torreya Partners: Torreya is a boutique advisory firm focused on life sciences M&A, licensing, and capital markets. Comparable to Xplico in serving pharma/biotech on valuation-intensive strategic transactions.
• Alacrita Consulting: Alacrita provides life science consulting including commercial assessment and valuation. Overlaps with Xplico's consulting practice serving biotech and pharma clients on project and company valuation.

Broad incumbents

• Anaplan: Anaplan is an enterprise planning platform covering FP&A, scenario modeling, and BI across industries. Comparable to Xplico Evaluator in providing financial planning and scenario analysis, but as a horizontal platform rather than a life science-verticalized tool.

Emerging players

• Vena Solutions: Vena offers an Excel-native FP&A and planning platform. Closely comparable to Xplico's Excel-based architecture while extending into cloud-native planning, budgeting, and scenario analysis workflows.
• Mosaic: Mosaic is an FP&A and business intelligence platform that competes in financial planning, scenario modeling, and KPI dashboards. Adjacent to Xplico's valuation and sensitivity analysis use cases, though positioned horizontally rather than for life sciences specifically.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/xplico

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xplico